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Abstract: The increasing prevalence of rich sources of data and the availability of electronic 
medical record databases and electronic registries opens tremendous opportunities for enhancing 
medical research. For example, controlled trials are ubiquitously used to investigate the effect of 
a medical treatment, perhaps dependent on a set of patient covariates, and traditional approaches 
have relied primarily on randomized patient sampling and allocation to treatment and control 
group. However, when covariate data for a large cohort group of patients have already been 
collected and are available in a database, one can potentially design a treatment/control sample 
and allocation that provides far better estimates of the covariate-dependent effects of the 
treatment. In this paper, we develop a new approach that uses optimal design of experiments 
(DOE) concepts to accomplish this objective. The approach selects the patients for the treatment 
and control samples upfront, based on their covariate values, in a manner that optimizes the 
information content in the data. For the optimal sample selection, we develop simple guidelines 
and an optimization algorithm that provides solutions that are substantially better than random 
sampling. Moreover, our approach causes no sampling bias in the estimated effects, for the same 
reason that DOE principles do not bias estimated effects. We test our method with a simulation 
study based on a testbed data set containing information on the effect of statins on low-density 
lipoprotein (LDL) cholesterol.  
Keywords: controlled trials, randomized trials, design of experiments, sampling from databases,  
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1 INTRODUCTION 
As more and higher-variety data become increasingly available in the information age, this 
offers revolutionary opportunities for enhancing medical research, e.g., in evaluating the effects 
of medical treatments in situation in which the effects depend on a set of patient covariates such 
as patient age, gender, ethnicity, etc. Controlled trials are used to investigate the effect of a 
treatment, and traditional controlled trials typically adopt random sampling and allocation of 
patients to the treatment and control groups in order to avoid biasing the treatment assignment 
and the estimated treatment effects [1]. These so-called randomized controlled trials involve 
several different types of randomization approaches, the simplest of which is unrestricted 
randomization. Also frequently used are restricted randomization approaches, including blocked 
randomization and stratified randomization [1-3]. A third type of approach is adaptive 
randomization, including covariate-adaptive randomization and response-adaptive randomization 
[2-4]. Most previous literature of the latter type focuses on the situation in which patients arrive 
sequentially, and, as each new patient arrives, one must decide to which group (treatment or 
control) the new patient should be allocated. There is also a large body of work on propensity 
scoring [5], in which one models the probability that a patient is selected for treatment as a 
function of the covariates and then incorporates this propensity score model into the analysis. 
However, propensity scoring is largely inapplicable to our problem, as it applies to observational 
data in which patients have already been selected for treatment based on other considerations. 
In contrast, taking advantage of the availability of databases containing covariate information 
on large numbers of patients, our proposed approach is to select upfront (in advance of 
conducting the study) a small but informative subset of patients from the database and to allocate 
each of the selected patients to either the treatment or the control group. The goal is to select and 
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allocate the patients judiciously, so as to maximize the amount of information in the data (as it 
pertains to estimating the covariate-dependent effects of the treatment factor) for a specified 
sample size. To motivate and illustrate the approach, consider a health management provider that 
contracts with large companies to offer diabetes outreach (and many other health management 
services) to employees of the companies. They would like to conduct a study to assess whether 
participation by an at-risk patient in a new diabetes outreach program (the treatment factor) is 
effective at lowering the patient's risk (as measured by an appropriate response variable); and, if 
so, they would like to quantify the effect of the treatment, recognizing that the effect may depend 
on the levels of a number of other covariates, such as various demographic, blood test and other 
health-related measures for that patient. They have such covariate information available for a 
large number of patients in their database, based on prior participation by the patients in other 
health management activities. Some form of controlled trial must be used, in which a small 
fraction of patients in the database are selected and allocated to either the control group or the 
treatment group. 
In this paper, we consider the more general situation in which the goal is to select a sample of 
patients, for participation in a controlled trial study, from an existing database containing patient 
covariates and then to allocate each patient to either the control or treatment group. Rather than 
using random sampling and allocation, we propose an optimal design of experiments (DOE) 
approach, in which patients are judiciously selected from the database and allocated based on 
their covariates. The DOE goal is to select and allocate the sample to maximize the information 
content of the data, as it pertains to estimating the covariate-dependent effects of the treatment 
factor. This is a computationally intractable combinatorial optimization problem using today’s 
technology. In light of this, we develop simple guidelines that provide insight into the nature of 
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the optimal sample and, based on this, an optimization algorithm for selecting the optimal sample. 
We refer to the approach as designed sampling from databases (DSD) for controlled trials, and 
we demonstrate that it provides a far more informative study than random sampling and 
allocation. 
We note that previous literature on covariate-adaptive randomization methods [6-10] has 
considered DOE-based criteria to allocate patients to treatment and control groups. However, the 
prior work considers patients that arrive sequentially, and each patient that arrives is allocated to 
the treatment or control group using DOE criteria. In contrast, in the present work we are also 
using DOE concepts to select the most appropriate sample of patients for the study, from among 
a very large set of patients in an existing database. Moreover, we also use a batch DOE strategy 
that selects and allocates the entire sample of patients in one shot, as opposed to a sequential 
DOE strategy that allocates patients one-at-a-time. For a specified sample size, optimal batch 
designs are generally more powerful than their suboptimal sequential design counterparts.  
It should be emphasized that although our DSD approach does not use random sampling, it 
introduces no sampling bias that might bias the estimated coefficients of the model. On first 
thought, one might speculate that any non-random sampling strategy may introduce a sampling 
bias. However, our DSD approach selects the sample based on patients' covariate data, without 
consideration of their response data. This is precisely what happens in any DOE, when one 
selects the factor settings (analogous to our selected patient covariate values) for each 
experimental run (analogous to one selected patient in the sample), without knowledge of the 
yet-to-be-realized response value for that run. Consequently, for the same reason that DOE does 
not result in a biased estimated model, neither does our DSD approach. Moreover, for the same 
reason that designed experiments with carefully selected factor settings generally result in far 
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more informative data than randomly selected factor settings, our DSD approach results in more 
informative data than random patient selection. 
The format of the remainder of the paper is as follows. In Section 2, we overview the DSD 
problem and describe the DSD sample design concepts. In Section 3, we describe the 
optimization algorithm for selecting and allocating the optimal DSD sample. In Section 4, we 
illustrate and evaluate the approach with an example. Section 5 concludes the paper and briefly 
discusses issues such as nonrandom sampling and bias, missing data, and the effect of patient 
nonparticipation.  
2 DSD SAMPLE DESIGN PRINCIPLES 
2.1 Problem overview  
We now formally describe the general underlying statistical model considered in this paper. 
Assume we have available a database containing covariate information (e.g., demographic and 
phenotypic information) for a large cohort group of 𝑁𝑁 patients. We are interested in the effect of 
a particular treatment on a response variable 𝑌𝑌 for the patients. Let 𝑧𝑧 = ±1 denote the treatment 
variable for a patient, i.e., 𝑧𝑧 = −1 if the patient is in the control group, and 𝑧𝑧 = 1 if the patient is 
in the treatment group. Suppose we intend to design and collect a sample of size 2𝑛𝑛 patients 
from this large cohort group of 𝑁𝑁 patients (2𝑛𝑛 ≪ 𝑁𝑁 typically), with 𝑛𝑛 patients allocated to the 
control group and 𝑛𝑛  allocated to the treatment group. Also suppose we have 𝑘𝑘  covariates {𝑥𝑥1, 𝑥𝑥2, . . . , 𝑥𝑥𝑘𝑘} available for each patient, and the treatment effect may depend on the covariates. 
To represent this situation, we assume the standard linear model with interactions between 
treatment and covariates: 
     𝑌𝑌𝑖𝑖 = 𝛿𝛿 + 𝛼𝛼𝑧𝑧𝑖𝑖 + 𝛽𝛽1𝑧𝑧𝑖𝑖𝑥𝑥𝑖𝑖1+ . . . +𝛽𝛽𝑘𝑘𝑧𝑧𝑖𝑖𝑥𝑥𝑖𝑖𝑘𝑘 + 𝛾𝛾1𝑥𝑥𝑖𝑖1+ . . . +𝛾𝛾𝑘𝑘𝑥𝑥𝑖𝑖𝑘𝑘+𝜀𝜀𝑖𝑖,   i = 1, 2, . . ., 2n        (1) 
7 
 
where the subscript 𝑖𝑖 is the patient index (or row index in the data array to which the regression 
model will be fit), 𝜀𝜀𝑖𝑖  is the random error term for the ith patient, 𝛉𝛉 = [𝛿𝛿  𝛼𝛼  𝛃𝛃𝑇𝑇  𝛄𝛄𝑇𝑇]𝑇𝑇  are the 
model parameters to be estimated, 𝛃𝛃 = [𝛽𝛽1,𝛽𝛽2, . . ., 𝛽𝛽𝑘𝑘]𝑇𝑇, and 𝛄𝛄 = [𝛾𝛾1,𝛾𝛾2, . . ., 𝛾𝛾𝑘𝑘]𝑇𝑇.  
Rewriting the model (1) as (and omitting the patient index) 
     𝑌𝑌 = 𝛿𝛿 + (𝛼𝛼 + 𝛽𝛽1𝑥𝑥1+ . . . +𝛽𝛽𝑘𝑘𝑥𝑥𝑘𝑘)𝑧𝑧 + 𝛾𝛾1𝑥𝑥1+ . . . +𝛾𝛾𝑘𝑘𝑥𝑥𝑘𝑘,                         (2) 
it follows that for a fixed set of covariate values {𝑥𝑥1, 𝑥𝑥2, . . . , 𝑥𝑥𝑘𝑘} for a patient, the covariate-
dependent effect of the treatment is 𝛼𝛼 + 𝛽𝛽1𝑥𝑥1+ . . . +𝛽𝛽𝑘𝑘𝑥𝑥𝑘𝑘. Consequently, our primary interest is 
in the parameters 𝛼𝛼 and 𝛃𝛃, and our objective is to select and allocate the sample of 2𝑛𝑛 patients so 
as to achieve the best possible estimates of these parameters of interest. We briefly discuss the 
issue of patient nonparticipation and missing covariate data in Section 5.  
2.2 Sample design concepts 
We use DOE principles to select and allocate the most informative patients to comprise the 
sample of 2𝑛𝑛  patients, from the database of 𝑁𝑁  patients, for the controlled trial study. In the 
traditional DOE literature, a number of methods have been developed to select the values of the 
design variables 𝐱𝐱 = {𝑥𝑥1, 𝑥𝑥2, . . . , 𝑥𝑥𝑘𝑘} for the experimental cases so as to optimize some measure 
of quality of the resulting fitted model. The most common optimal DOE criteria when fitting 
linear regression models are the so-called “alphabetic” optimality criteria (e.g., D-optimality) 
[11,12], and algorithmic design optimization is quite well developed [13-15].  
Existing optimal DOE methods are not directly applicable to our situation, because of our 
restriction that we must sample patients from some larger set of patients in an existing database. 
First, our design space (the set of feasible values for 𝐱𝐱) is neither a continuous domain (common 
in traditional DOE when the input factors are continuous variables), nor a region or subregion of 
a grid (common in traditional DOE when the input factors have discrete settings). Our design 
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space is the set of existing 𝐱𝐱 values for the 𝑁𝑁 patients in the database. For large 𝑁𝑁, there are a 
great many possible 𝐱𝐱 values to consider, and these data points typically have quite irregular 
structure due to issues such as multicollinearity, clusters, outliers, etc. in the 𝐱𝐱-space. Second, 
when considering whether/how to modify an 𝐱𝐱  value in the design, its elements cannot be 
modified independently, as in the coordinate exchange algorithm of Meyer and Nachtsheim [15] 
(the most widely used DOE optimization algorithm), because only the fixed set of 𝐱𝐱 values in the 
available data set are permissible. Our DOE optimization approach is closest to that of Ouyang, 
et al. [16], who developed an optimal DOE-based algorithm for selecting a validation sample of 
medical records for chart review from a large database of unreliable, error-prone records. Their 
optimal DOE criterion pertained to fitting a logistic regression model to the validated data, but 
they did not consider the problem of allocating patients to control/treatment groups in a 
controlled trial study. 
In this paper, we use a D-optimality criterion to select and allocate our sample of 2𝑛𝑛 patients. 
That is, we choose the sample to maximize the determinant of Fisher information matrix for the 
fitted linear regression model. To develop this approach, rewrite Model (1) in regression matrix 
form as  
     𝐘𝐘 = 𝐌𝐌𝛉𝛉 + 𝛆𝛆,                 (3) 
where 𝐘𝐘 = [𝑌𝑌1,𝑌𝑌2, . . ., 𝑌𝑌2𝑛𝑛]𝑇𝑇 , and 𝛆𝛆 = [𝜀𝜀1, 𝜀𝜀2, . . ., 𝜀𝜀2𝑛𝑛]𝑇𝑇  with each 𝜀𝜀𝑖𝑖 ~𝑁𝑁(0,𝜎𝜎2)  assumed 
Gaussian and independent. It is straightforward to show that the overall regression design matrix 
is 
 𝐌𝐌 = �𝟏𝟏 
𝟏𝟏 −𝟏𝟏 𝟏𝟏 −𝐗𝐗− 𝐗𝐗+ 𝐗𝐗−𝐗𝐗+�, 
where 𝟏𝟏 is an n×1 vector of ones, 𝐗𝐗− is the n×k design matrix for the group of n control patients, 
and 𝐗𝐗+ is the n×k design matrix for the group of n treatment patients. That is,  
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 𝐗𝐗− = �𝑥𝑥11 ⋯ 𝑥𝑥1𝑘𝑘⋮ ⋮
𝑥𝑥𝑛𝑛1 ⋯ 𝑥𝑥𝑛𝑛𝑘𝑘
� 
for the group of n control patients, with the first subscript on 𝑥𝑥𝑖𝑖𝑖𝑖 indicating the patient index. The 
n×k matrix 𝐗𝐗+ is defined similarly, but for the group of n treatment patients. 
From standard linear regression theory [17], the Fisher information matrix is 𝐅𝐅 = 1
𝜎𝜎2
𝐌𝐌𝑇𝑇𝐌𝐌, 
and the covariance matrix of the estimated regression parameter 𝛉𝛉� is 𝐅𝐅−𝟏𝟏. In our case, 
 𝐅𝐅 = 1
𝜎𝜎2
�
𝟏𝟏𝑇𝑇 𝟏𝟏𝑇𝑇
−𝟏𝟏𝑇𝑇 𝟏𝟏𝑇𝑇
−𝐗𝐗−
𝑇𝑇 𝐗𝐗+
𝑇𝑇
𝐗𝐗−
𝑇𝑇 𝐗𝐗+
𝑇𝑇
� �𝟏𝟏 
𝟏𝟏 −𝟏𝟏 𝟏𝟏 −𝐗𝐗− 𝐗𝐗+ 𝐗𝐗−𝐗𝐗+� 
  = 𝑛𝑛
𝜎𝜎2
⎣
⎢
⎢
⎢
⎡
2 0 𝐱𝐱�+𝑇𝑇 − 𝐱𝐱�−𝑇𝑇 𝐱𝐱�+𝑇𝑇 + 𝐱𝐱�−𝑇𝑇0 2 𝐱𝐱�+𝑇𝑇 + 𝐱𝐱�−𝑇𝑇 𝐱𝐱�+𝑇𝑇 − 𝐱𝐱�−𝑇𝑇
𝐱𝐱�+
𝑇𝑇 − 𝐱𝐱�−
𝑇𝑇 𝐱𝐱�+
𝑇𝑇 + 𝐱𝐱�−𝑇𝑇 𝐒𝐒+ + 𝐒𝐒− 𝐒𝐒+ − 𝐒𝐒−
𝐱𝐱�+
𝑇𝑇 + 𝐱𝐱�−𝑇𝑇 𝐱𝐱�+𝑇𝑇 − 𝐱𝐱�−𝑇𝑇  𝐒𝐒+ − 𝐒𝐒− 𝐒𝐒+ + 𝐒𝐒− ⎦⎥⎥
⎥
⎤
,            (4) 
where 𝐒𝐒+ = 1𝑛𝑛 𝐗𝐗+𝑇𝑇𝐗𝐗+  and 𝐒𝐒− = 1𝑛𝑛 𝐗𝐗−𝑇𝑇𝐗𝐗−  are similar to the k×k sample covariance matrices 
(except that the sample average is not subtracted from the data) for the vector 𝐱𝐱 = {𝑥𝑥1, 𝑥𝑥2, . . . , 𝑥𝑥𝑘𝑘} 
over the treatment and control groups, respectively, and 𝐱𝐱�+  and 𝐱𝐱�−  are the k×1 sample average 
vectors for 𝐱𝐱 over the treatment and control groups, respectively.   
 From (4), we can reduce aliasing between the estimates of 𝛼𝛼 , 𝛃𝛃, and 𝛄𝛄 by imposing the 
following design constraints (which will be ensured later in the optimization algorithm): 
 𝐱𝐱�+ ≈ 𝐱𝐱�−   and  𝐒𝐒+ ≈ 𝐒𝐒−                (5) 
The interpretation of these constraints is that we require that the sample average vectors and 
sample covariance matrices of 𝐱𝐱 to be similar for the control and treatment groups. This clearly 
has intuitive appeal, as one would expect that the patients chosen for the treatment group should 
be statistically similar to the patients chosen for the control group. It also has important 
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implications that enable a computationally feasible, two-stage design optimization algorithm (see 
Section 3). With these constraints, the Fisher information matrix (4) becomes 
 𝐅𝐅 ≅ 𝑛𝑛
𝜎𝜎2
⎣
⎢
⎢
⎢
⎡
2 0 𝟎𝟎 𝐱𝐱�+𝑇𝑇 + 𝐱𝐱�−𝑇𝑇0 2 𝐱𝐱�+𝑇𝑇 + 𝐱𝐱�−𝑇𝑇 𝟎𝟎
𝟎𝟎 𝐱𝐱�+ + 𝐱𝐱�− 𝐒𝐒+ + 𝐒𝐒− 𝟎𝟎
𝐱𝐱�+ + 𝐱𝐱�− 𝟎𝟎  𝟎𝟎 𝐒𝐒+ + 𝐒𝐒− ⎦⎥⎥
⎥
⎤
 
    = 𝑛𝑛
𝜎𝜎2
⎣
⎢
⎢
⎢
⎡
2 0 𝟎𝟎 2𝐱𝐱�𝑇𝑇0 2 2𝐱𝐱�𝑇𝑇 𝟎𝟎
𝟎𝟎 2𝐱𝐱� 1
𝑛𝑛
𝐗𝐗𝑇𝑇 𝐗𝐗 𝟎𝟎2𝐱𝐱� 𝟎𝟎  𝟎𝟎 1
𝑛𝑛
𝐗𝐗𝑇𝑇 𝐗𝐗⎦
⎥
⎥
⎥
⎤
,              (6) 
where 𝟎𝟎 denotes a vector or matrix of zeros of appropriate dimension, 𝐗𝐗 = �𝐗𝐗−
𝐗𝐗+
� is the 2n×k 
design matrix for 𝐱𝐱, and 𝐱𝐱� is k×1 average vector for 𝐱𝐱, both of which are over the entire sample 
of 2n patients.  
By inverting the expression (6) and using results on the inverse of a partitioned matrix [18], 
the covariance matrix of 𝛉𝛉� is 
𝐅𝐅−1 ≅
𝜎𝜎22𝑛𝑛
⎣
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎡ 11 − 2𝑛𝑛𝐱𝐱�𝑇𝑇(𝐗𝐗𝑇𝑇 𝐗𝐗)−1𝐱𝐱� 0 𝟎𝟎 −𝐱𝐱�𝑇𝑇 �𝐗𝐗𝑇𝑇 𝐗𝐗2𝑛𝑛 − 𝐱𝐱�𝐱𝐱�𝑇𝑇�−10 11 − 2𝑛𝑛𝐱𝐱�𝑇𝑇(𝐗𝐗𝑇𝑇 𝐗𝐗)−1𝐱𝐱� −𝐱𝐱�𝑇𝑇 �𝐗𝐗𝑇𝑇 𝐗𝐗2𝑛𝑛 − 𝐱𝐱�𝐱𝐱�𝑇𝑇�−1 𝟎𝟎
𝟎𝟎 −�
𝐗𝐗𝑇𝑇 𝐗𝐗2𝑛𝑛 − 𝐱𝐱�𝐱𝐱�𝑇𝑇�−1 𝐱𝐱� �𝐗𝐗𝑇𝑇 𝐗𝐗2𝑛𝑛 − 𝐱𝐱�𝐱𝐱�𝑇𝑇�−1 𝟎𝟎
−�
𝐗𝐗𝑇𝑇 𝐗𝐗2𝑛𝑛 − 𝐱𝐱�𝐱𝐱�𝑇𝑇�−1 𝐱𝐱� 𝟎𝟎  𝟎𝟎 �𝐗𝐗𝑇𝑇 𝐗𝐗2𝑛𝑛 − 𝐱𝐱�𝐱𝐱�𝑇𝑇�−1 ⎦⎥⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎤
 
 = 𝜎𝜎2
2𝑛𝑛
�
1 + 𝐱𝐱�𝑇𝑇𝐒𝐒−1𝐱𝐱� 0 𝟎𝟎 −𝐱𝐱�𝑇𝑇𝐒𝐒−10 1 + 𝐱𝐱�𝑇𝑇𝐒𝐒−1𝐱𝐱� −𝐱𝐱�𝑇𝑇𝐒𝐒−1 𝟎𝟎
𝟎𝟎 −𝐒𝐒−1𝐱𝐱� 𝐒𝐒−1 𝟎𝟎
−𝐒𝐒−1𝐱𝐱� 𝟎𝟎  𝟎𝟎 𝐒𝐒−1 �,           (7) 
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where 𝐒𝐒 = 𝐗𝐗𝑇𝑇 𝐗𝐗
2𝑛𝑛
− 𝐱𝐱�𝐱𝐱�𝑇𝑇 is the sample covariance matrix of 𝐱𝐱 over the entire sample of 2n patients, 
and we have used the relationship (𝐗𝐗𝑇𝑇 𝐗𝐗)−1 = 1
2𝑛𝑛
�𝐒𝐒−1 −
𝐒𝐒−1𝐱𝐱�𝐱𝐱�𝑇𝑇𝐒𝐒−1
1+𝐱𝐱�𝑇𝑇𝐒𝐒−1𝐱𝐱�
�.  
From (7), the covariance matrix of the regression estimates of 𝛼𝛼 and 𝛃𝛃 is  
 𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃�� = 𝜎𝜎2
2𝑛𝑛
�1 + 𝐱𝐱�𝑇𝑇𝐒𝐒−1𝐱𝐱� −𝐱𝐱�𝑇𝑇𝐒𝐒−1
−𝐒𝐒−1𝐱𝐱� 𝐒𝐒−1
�.           (8) 
Because of the symmetry and block structure of (7), it follows that 𝐶𝐶𝐶𝐶𝐶𝐶�𝛿𝛿,𝛄𝛄�� = 𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃��, and 
that �𝛿𝛿,𝛄𝛄��  are uncorrelated (unaliased) with �𝛼𝛼�,𝛃𝛃�� . Consequently, |𝐅𝐅−1| = �𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃��� ×
�𝐶𝐶𝐶𝐶𝐶𝐶�𝛿𝛿,𝛄𝛄��� = �𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃���2 , so that minimizing the overall D-optimality criterion |𝐅𝐅−1|  is 
equivalent to minimizing �𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃���, which is the D-optimality criterion for the parameters of 
primary interest. Using (8) and results on the determinant of a partitioned matrix [19], we have   
 �𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃��� = �𝜎𝜎2
2𝑛𝑛
�
𝑘𝑘+1 |𝐒𝐒−1| × |1 + 𝐱𝐱�𝑇𝑇𝐒𝐒−1𝐱𝐱� − 𝐱𝐱�𝑇𝑇𝐒𝐒−1𝐒𝐒𝐒𝐒−1𝐱𝐱�| = �𝜎𝜎2
2𝑛𝑛
�
𝑘𝑘+1 |𝐒𝐒−1|.      (9) 
Consequently, our DSD optimal design strategy is simply to minimize |𝐒𝐒−1| or, equivalently, to 
maximize |𝐒𝐒|, the determinant of the sample covariance matrix of the full sample of 2n patients, 
while ensuring constraints (5). This has important implications regarding the tractability and 
computational feasibility of the optimization algorithm for selecting and allocating the patients, 
as discussed in Section 3. 
3 DESIGN OPTIMIZATION ALGORITHM 
Henceforth, we assume that, as a preprocessing step, one has standardized the k covariates by 
subtracting their average values and dividing by their standard deviations over all 𝑁𝑁 patients in 
the database. This is necessary for the criteria like D-optimality to be meaningful, and it is also 
recommended for improving numerical issues in regression analyses. 
12 
 
In light of the developments in Section 2.2, we use a two-stage algorithm to optimize the 
design. Specifically, in order to minimize �𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃���, Eq. (6c) shows that the entire sample of 
2n patients can be chosen to maximize the determinant of 𝐒𝐒, the sample covariance matrix of the 
covariates for the 2n patients. The salient implication of this result is that the 2n patients can be 
chosen without regard to the treatment versus control groups allocation decisions (providing 
constraints (5) are satisfied), resulting in a far more computationally tractable optimization 
problem. 
Consequently, in Stage 1 of the design algorithm, we select 2n patients from the large 
database of N patients to maximize |𝐒𝐒| = �𝐗𝐗𝑇𝑇 𝐗𝐗
2𝑛𝑛
− 𝐱𝐱�𝐱𝐱�𝑇𝑇�, which is based entirely on the covariate 
values of the patients. In Stage 2, we will allocate these 2n patients into the treatment or control 
groups to ensure that 𝐱𝐱�+ ≈ 𝐱𝐱�−  and 𝐒𝐒+ ≈ 𝐒𝐒− , i.e., to ensure constraints (5) that the sample mean 
vectors and covariance matrices for the treatment and control groups are equivalent. The 
remainder of this section describes the optimization algorithms for accomplishing this. 
Regarding Stage 1, choosing the 2n out of N patients that exactly maximize �𝐗𝐗
𝑇𝑇 𝐗𝐗
2𝑛𝑛
− 𝐱𝐱�𝐱𝐱�𝑇𝑇� is a 
computationally intractable combinatorial optimization problem for large N. Consequently, we 
use a backward stepwise (greedy) approach by which we start with all 𝑁𝑁 patients in the sample 
and, at each step, remove the single patient that least reduces �𝐗𝐗
𝑇𝑇 𝐗𝐗
2𝑛𝑛
− 𝐱𝐱�𝐱𝐱�𝑇𝑇�, stopping when we 
have reduced the number of patients to the desired 2n. For a related optimization problem, in 
terms of solution quality and computational complexity, Ouyang, et al. [16] found the backwards 
stepwise approach to be more effective than a forwards stepwise approach or a 
forwards/backwards hybrid approach.  
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Let p denote the number of patients in the sample at the current step, let 𝐱𝐱�𝑝𝑝 denote the 𝑘𝑘 × 1 
sample average column vector for the p patients, and let 𝐗𝐗𝑝𝑝 denote the 𝑝𝑝 × 𝑘𝑘 design matrix for 
the p patients. Selecting the next patient to remove from the sample requires calculating 
| �𝐗𝐗𝑝𝑝−1�𝑇𝑇𝐗𝐗𝑝𝑝−1
𝑝𝑝−1
− 𝐱𝐱�𝑝𝑝−1(𝐱𝐱�𝑝𝑝−1)𝑇𝑇| a total of p times (once for removing each of the p patients), the 
computational expense of which can be substantially reduced using the following recursive 
expressions. Let r denote the index of the patient considered for removal and 𝐱𝐱𝑟𝑟  their 𝑘𝑘 × 1 
vector of predictors. Noting that (𝐗𝐗𝑝𝑝−1)𝑇𝑇𝐗𝐗𝑝𝑝−1 = (𝐗𝐗𝑝𝑝)𝑇𝑇𝐗𝐗𝑝𝑝 − 𝐱𝐱𝑟𝑟(𝐱𝐱𝑟𝑟)𝑇𝑇, we can recursively (going 
from 𝑝𝑝 → 𝑝𝑝 − 1) update all needed quantities via 
 |(𝐗𝐗𝑝𝑝−1)𝑇𝑇𝐗𝐗𝑝𝑝−1| = |(𝐗𝐗𝑝𝑝)𝑇𝑇𝐗𝐗𝑝𝑝|(1 − (𝐱𝐱𝑟𝑟)𝑇𝑇[(𝐗𝐗𝑝𝑝)𝑇𝑇𝐗𝐗𝑝𝑝]−1𝐱𝐱𝑟𝑟),          (10) 
 𝐱𝐱�𝑝𝑝−1 = 𝑝𝑝𝐱𝐱�𝑝𝑝−𝐱𝐱𝑟𝑟
𝑝𝑝−1
, 
 [(𝐗𝐗𝑝𝑝−1)𝑇𝑇𝐗𝐗𝑝𝑝−1]−1 = [(𝐗𝐗𝑝𝑝)𝑇𝑇𝐗𝐗𝑝𝑝]−1 + �(𝐗𝐗𝑝𝑝)𝑇𝑇𝐗𝐗𝑝𝑝�−1𝐱𝐱𝑟𝑟(𝐱𝐱𝑟𝑟)𝑇𝑇�(𝐗𝐗𝑝𝑝)𝑇𝑇𝐗𝐗𝑝𝑝�−1
1−(𝐱𝐱𝑟𝑟)𝑇𝑇[(𝐗𝐗𝑝𝑝)𝑇𝑇𝐗𝐗𝑝𝑝]−1𝐱𝐱𝑟𝑟 , and         (11) 
 ��𝐗𝐗
𝑝𝑝−1�
𝑇𝑇
𝐗𝐗𝑝𝑝−1
𝑝𝑝−1
− 𝐱𝐱�𝑝𝑝−1(𝐱𝐱�𝑝𝑝−1)𝑇𝑇�  
  = ( 1
𝑝𝑝−1
)𝑘𝑘|(𝐗𝐗𝑝𝑝−1)𝑇𝑇𝐗𝐗𝑝𝑝−1|(1 − (𝑝𝑝 − 1)(𝐱𝐱�𝑝𝑝−1)𝑇𝑇[(𝐗𝐗𝑝𝑝−1)𝑇𝑇𝐗𝐗𝑝𝑝−1]−1𝐱𝐱�𝑝𝑝−1).       (12) 
Eqs. (10)—(12) follow from standard results on the determinant and the inverse of a rank-
one modification of a matrix [20,21]. Eqs. (10)—(12) are iteratively executed for p = N, N−1, . . ., 
2n+1, until the desired sample size 2𝑛𝑛 is reached. On each iteration, they are repeated for each 
patient (i.e., each 𝐱𝐱𝑟𝑟) in the current sample of p patients.  
In Stage 2, after the 2n patients are selected in Stage 1, half of the 2n patients must be 
allocated to the control group and the other half to the treatment group. The Stage 2 criterion is 
to ensure that 𝐱𝐱�+ ≈ 𝐱𝐱�−  and 𝐒𝐒+ ≈ 𝐒𝐒−  per constraints (5), in which case the overall optimization 
criterion �𝐶𝐶𝐶𝐶𝐶𝐶�𝛼𝛼�,𝛃𝛃��� depends only on the overall 𝐒𝐒 for all 2n patients. We begin by randomly 
allocating n patients to the control group (comprising the rows of 𝐗𝐗− ) and the other n patients to 
the treatment group (comprising the rows of 𝐗𝐗+ ), for which the constraints (5) will typically be 
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approximately satisfied. We then follow up by exchanging a pair of patients between the 
treatment and control groups, with the pair chosen to minimize the criterion ||𝐱𝐱�+ − 𝐱𝐱�− ||2 +||𝐒𝐒+ − 𝐒𝐒− ||2 after the exchange. This exchange procedure is repeated until no further reduction 
in the criterion can be achieved. Each exchange requires searching over 𝑛𝑛2 possible pairs of 
patients.   
4  EXAMPLE AND PERFORMANCE EVALUATION 
To evaluate our approach, we used a testbed data set containing information on the effect of 
statins (the treatment variable, z) on low-density lipoprotein (LDL) cholesterol (the response 
variable, y). The results are not meant to represent scientific findings, but rather to illustrate the 
capabilities of our DSD method. We considered four covariates (𝑥𝑥1  to 𝑥𝑥4), namely age, body 
mass index (bmi), diastolic blood pressure (bp_diastolic) and triglycerides (tri). A total of N = 
11,080 patient records of these four covariates were considered from Northwestern Memorial 
Hospital EMR database from January 2006 to December 2010. The average and standard 
deviation are, respectively, 58 and 13.5 (for age), 30.19 and 7.45 (for bmi); 77.6 and 11.76 
(bp_diastolic), and 117.23 and 71.43 (tri). All four covariates values were standardized prior to 
the subsequent analyses.  
We applied our DSD approach to select a sample of 2𝑛𝑛 = 1,000 patients for a hypothetical 
controlled-trial study, based on their covariate values for the real data set. To evaluate the 
performance of the approach, we calculated mean square errors (MSEs) for the parameters of 
interest that would result from fitting the regression model (1) to the selected sample. Notice that 
the MSEs can be obtained directly from the diagonal elements of the inverse of 𝐅𝐅 in Eq. (4), 
which depends only on n, 𝜎𝜎, and the covariate values for the selected sample. Notice also that 𝜎𝜎2 
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multiplies 𝐅𝐅−𝟏𝟏 , and, hence, the relative MSE performance when comparing two different 
methods for selecting the sample is independent of 𝜎𝜎. Consequently, we will assume a single 
value 𝜎𝜎 = 0.3 in the following comparisons, which was approximately the standard deviation of 
LDL cholesterol over the full data set.  
We used Monte Carlo (MC) simulation with 10,000 MC replicates to compare the MSEs of 
the estimated parameters 𝛉𝛉� that resulted from using our DSD approach to select and allocate the 
sample, versus randomly selecting a total 2𝑛𝑛 patients and then randomly allocating half of them 
to the treatment group and the other half to the control group. For the random sampling method, 
on each MC replicate we selected a different random sample of 2𝑛𝑛  patients. For our DSD 
method, the sample of 2𝑛𝑛 patients do not vary from replicate to replicate, since they are selected 
from the original dataset of N patients. For this example, the MSEs after the final Stage 2 
allocation of the DSD method were very consistent for different "initial guess" random 
allocations at the beginning of Stage 2. More generally, if the MSEs are found to depend on the 
initial guess, then one should use multiple initial guesses and choose the one that results in the 
smallest MSEs. The average MSEs (averaged across the 10,000 MC replicates) for the treatment 
factor (𝛼𝛼�) and treatment-by-covariate interactions (𝛃𝛃�) are shown in Table 1.  
Remarkably, Table 1 shows that the MSEs for the estimates of the interaction terms (𝛃𝛃�) from 
our DSD approach are one-third to one-fourth the MSEs from random sampling. Notice that the 
MSE for 𝛼𝛼� is very slightly larger (worse) for the DSD method than for random sampling. This is 
not surprising, as it is straightforward to show from (4) that a lower bound on the MSE of 𝛼𝛼� is 𝜎𝜎
2
2𝑛𝑛
, 
and this lower bound is achieved when 𝐱𝐱�+ = 𝐱𝐱�− = 𝟎𝟎 is satisfied exactly. Stage 2 of our DSD 
algorithm ensures that 𝐱𝐱�+ ≅ 𝐱𝐱�− , but not necessarily that they are both close to 𝟎𝟎 (although the 
latter often will also be the case, since the covariates have been standardized over the complete 
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set of N patients). When sample size 2𝑛𝑛 is large, pure random sampling typically does a good job 
of satisfying the condition 𝐱𝐱�+ ≅ 𝐱𝐱�− ≅ 𝟎𝟎. Hence, it has a slightly lower MSE for 𝛼𝛼�. However, it 
is important to recognize that the dramatic reduction in the MSE of 𝛃𝛃� for the DSD approach, 
relative to random sampling, far outweighs the slight increase in the MSE of 𝛼𝛼�.  
5  CONCLUSIONS 
This paper presents a method that uses DOE concepts to judiciously select patients for a 
controlled trial study, from among a large patient database containing patient covariate 
information. The two-stage optimization algorithm in our DSD approach first selects in Stage 1 
the overall sample of 2n patients to enter into the study, and then in Stage 2 subsequently 
allocates the 2n patients in the selected cohort to either treatment and control groups. 
Interestingly, we have shown that in order to optimally select the patients, it is sufficient to 
consider the sample covariance matrix of the patient covariates over the entire sample of 2n 
patients, prior to consideration of their allocation to treatment/control groups. Then, in Stage 2, 
one simply allocates the 2n patients to either the treatment group or control group to ensure that 
the within-group mean vectors and covariance matrices are approximately equal. Exploiting 
these findings, we have developed a powerful, yet computationally tractable, optimization 
procedure for optimal sample design. We have demonstrated via an example that the proposed 
DSD approach can result in a substantially lower MSE for the estimates of the covariate-
dependent effects of the treatment, relative to random sampling. From an alternative viewpoint, 
our findings imply that to ensure a desired MSE for the parameter estimates, much lower sample 
sizes are needed when using our DSD approach to select patients from a database, versus random 
sampling. This would result in significant cost savings when conducting such studies.  
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We reiterate that our DSD approach introduces no sampling bias in the estimated coefficients, 
nor prevents conclusions on the causal effects of the treatment from being drawn, even though it 
does not use random sampling. This may sound surprising to some, given the prevalence of 
random sampling in clinical trials. However, keep in mind that fundamental DOE principles 
involve a very similar "nonrandom" mechanism. In any DOE, one judiciously selects a specific 
combination of factor settings for each experimental run, and these factor settings are not chosen 
randomly. They are, however, chosen without knowledge of the yet-to-be-realized response 
value for that run, and this is what avoids the introduction of any bias in the estimated factor 
effects due to this type of non-random sampling. Otherwise, if DOE principles introduced a bias, 
then DOE would not be used as ubiquitously as it is. Something quite similar occurs in our DSD 
approach. We judiciously select a specific combination of patient covariate data (analogous to 
the factor settings) for each selected patient (analogous to each experimental run) in the entire 
sample (analogous to the entire experiment), and the patients are selected without consideration 
of their yet-to-be-realized response data. Consequently, like in DOE, the nonrandom designed 
sample selection in our DSD approach does not cause any biases. In fact, the judicious 
(nonrandom) sample selection is precisely what results in a more informative data set being 
collected than would random sampling, much like how using optimal DOE principles results in a 
much more informative experiment than if the factor settings were chosen randomly.  
We close with some words on the robustness of our approach to missing data and selected 
patients who opt not to participate in the study. Because we are selecting patients from a large 
database with patient covariate values, for any patient with missing covariate data we can simply 
exclude them from consideration. This ensures that all of the selected patients have no missing 
covariate data. Regarding patients who are selected for either the treatment or control groups but 
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opt not to participate, this clearly affects the information content in the final (participating) study 
cohort and nullifies its optimality. By design of the DSD approach (because after selecting the 
sample of 2n patients we nearly randomly allocate them to treatment and control groups), we 
expect that the difference in participation rates between patients selected for the treatment and 
control groups should be relatively tractable. As future work, we are currently investigating how 
to incorporate this information into the DSD design strategy so the final participating sample has 
near-optimality properties.   
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Table 1. Performance comparison of our DSD approach versus random sampling. The 
numbers in the table are MSE values for the estimated parameters for the treatment factor 
and its interactions with the covariates, averaged across 10,000 MC replicates. 
 α� β�1 β�2 β�3 β�4 
random sampling 9.07E-05 9.33E-05 9.63E-05 9.35E-05 9.96E-05 
DSD 9.71E-05 3.85E-05 2.71E-05 2.91E-05 2.05E-05 
 
